Der Human Monoklonal anti-OC126 (Abagovomab Biosimilar) Antikörper wird verwendet zum Nachweis von OC126 (Abagovomab Biosimilar) in Proben von Maus. Er wurde validiert für ELISA und WB.
Research Grade
Reaktivität: Human
Wirt: Maus
Monoclonal
unconjugated
Recombinant Antibody
Beschränkungen
Nur für Forschungszwecke einsetzbar
Buffer
PBS buffer PH7.5
Lagerung
-80 °C
Informationen zur Lagerung
store at -80°C
Target
OC126 (Abagovomab Biosimilar)
Substanzklasse
Biosimilar
Hintergrund
Abagovomab is a murine monoclonal anti-idiotypic antibody (MW: 165-175 kDa), produced by a mouse hybridoma and generated against OC125, which serves to functionally imitate the human cancer antigen 125 (CA-125). Abagovomab has been developed by the pharmaceutical company Menarini for the treatment of ovarian cancer. It (ab2) shows high affinity for the paratope of ab1, and binding of ab2 to Ab1 is almost completely inhibited (93%) by the nominal antigen. The administration of F(ab')2 fragments of abagovomab to rats produces anti-CA-125 immunity with the production of IgG and IgM anti-anti-idiotypic antibodies (ab3) that bind both to abagovomab and CA-125. Non-MHC restricted cell-mediated cytotoxicity for NIH OVCAR3 cell lines is also demonstrated.